Skip to main content

One Wales

06/04/2023
OWMAG panel members

One Wales Medicines Assessment Group membership

19/09/2024
One Wales Medicines Process work programme September 2024


07/08/2023
One Wales Work programme August 2023
One Wales Medicines Process work programme July 2024.pdf
10/07/2024
Nivolumab (OW28) One Wales Interim Decision with rationale Jul 24.pdf


10/07/2024
Equality and Health Impact Assessment Nivolumab 2024.pdf


10/07/2024
Nivolumab (OW28) Evidence Status Report Jun 2024.pdf


27/08/2020
Evidence Status Report: opicapone (Ongentys) OW11
18/03/2024
OWMAG Meeting Minutes 19 June 2023


08/11/2022
One Wales Interim Decision with evidence review. Vonicog alfa for children with VWD (OW19 2023 review)
12/10/2021
One Wales Interim Decision (with start stop criteria and evidence review): Azacitidine for the treatment of progressive angioimmunoblastic T-cell lymphoma (OW16 2023 review)
03/08/2023
One Wales Interim Descision with evidence review. Mepolizumab for CEP. OW15. 2023.pdf


03/07/2023
One Wales Work programme July 2023


17/03/2022
Medicine request form for consideration for the One Wales Medicines process

We welcome suggestions for medicines to be considered via the One Wales Medicines process from Individual Patient Funding Request (IPFR) panels, Welsh Health Specialised Services Committee (WHSSC), clinicians (ideally through clinical networks), chief pharmacists, formulary pharmacists or medicines and therapeutics committees. The process is driven by identification of unmet clinical need by the service and therefore we cannot accept requests from pharmaceutical companies or from members of the public.

11/05/2023
OWMAG meeting minutes 20 March 2023
13/06/2021
One Wales Medicines process policy

The One Wales Medicines Process, (previously known as the One Wales Interim Commissioning process) was developed in 2015, following a review of the individual patient funding request process. It introduced an alternative route to access a medicine (or medicines) for a clearly defined and specific cohort of patients in the absence of health technology appraisal advice. One Wales decisions are based on the available evidence of clinical effectiveness and cost-effectiveness. Once approved, these interim decisions ensure that there is equitable access to these medicines across NHS Wales. This document explains when this process may be used and how it works.

23/02/2023
OWMAG meeting minutes 19 Dec 2022


06/01/2021
One Wales Interim Decision: denosumab for male osteoporosis. OW07. 2023
19/01/2021
Evidence Status Report: mepolizumab for CEP. OW15. 2019.pdf
17/05/2021
OWID with evidence review. Mepolizumab for chronic eosinophilic pneumonia. OW15. 2021
Follow AWTTC: